Community Based Management of Ventricular Assist Devices by Marnie Rodger & Vivek Rao
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
10 
Community Based Management 
of Ventricular Assist Devices 
Marnie Rodger RN MN and Vivek Rao MD PhD 
University Health Network 
Canada 
1. Introduction 
Heart failure is a progressive disease associated with high mortality and poor quality of life. 
It is an increasingly common condition that affects over 5 million Americans with 670 000 
new cases diagnosed each year (Lloyd-Jones et al., 2010). Patients with end stage heart 
failure have a grave prognosis even with maximal medical therapy. Hershberger and 
colleagues reported that the survival of inotrope dependent patients with end stage heart 
failure was 51 %, 26% and 6 % at 3, 6, 12 months respectively (Hershberger et al., 2003). 
Ventricular assist devices (VADs) have been in use for over two decades as a treatment 
option for patients with advanced heart failure. These mechanical pumps provide 
hemodynamic support to patients as bridges to cardiac transplantation or destination 
therapy for transplant ineligible patients. Development of VAD technology and 
improvements in medical management have allowed individuals with VADs to be 
discharged from hospitals to their communities. As the number of patients on VAD support 
continues to rise and more patients are discharged from hospital, outpatient management of 
VAD patients has become a critical component of mechanical circulatory support programs. 
This chapter will examine the literature on outpatient VAD support. The fundamental 
elements of a safe and effective discharge process will be summarized. VAD outpatient 
outcomes and community based management of device related complications will be 
discussed. 
The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive 
Heart Failure (REMATCH) trial was a landmark clinical trial that demonstrated that the 
use of left ventricular assist devices (LVADs) in patients with advanced heart failure 
resulted in a 48% reduction in the risk of death as compared to optimal medical 
management. The REMATCH trial randomized patients with end stage heart failure who 
were ineligible for cardiac transplantation to either LVAD therapy or optimal medical 
management. One year survival was 52% in the LVAD group and 25% in the medical 
therapy group and 2 year survival was 23 and 8 % respectively. The quality of life was 
significantly improved at one year in the device group. However, the frequency of serious 
adverse events in the device group was 2.35 times that in the medical therapy group (Rose 
et el., 2001). Despite substantial survival benefit and significant better quality of life, the 
study revealed that morbidity and mortality associated with the use of LVADs is 
considerable.  
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2. Device designs 
A variety of long term VADs have been developed to benefit patients with end stage heart 
failure. Devices are classified based on a number of characteristics including device location 
and the method by which the device supports circulation. There are three generations of 
VADs currently available for use. First generation pumps use pulsatile action with volume 
displacement.  Pulsatile VADs have multiple moving components that are vulnerable to 
failure over time. Second generation VADs are designed to address some of the problems 
seen with the first generation VADs. Developed over the past decade, second generation 
VADs are rotary pumps that provide continuous blood flow. Nonpulsatile flow allows for 
smaller and quieter devices with less mechanical parts. Continuous axial blood flow is 
generated by an impeller rotating at high speeds on mechanical bearings. The newest 
version, third generation VADs are continuous axial or centrifugal flow devices with 
bearingless impellers or rotors that are magnetically or hydrodynamically levitated (Visouli 
& Pitsis, 2008).  There exist a number of different VADs and a complete review of all the 
devices is beyond the scope of this chapter. Table 1 briefly reviews some of the long term 
devices, their mode of action and current status.  
 
Device Manufacturer Position Type  Status 
Novacor® 
WorldHeart 
Corporation, Salt 
Lake City, UT, USA
Intracorporeal Pulsatile 
No longer in use 
since 2008 
HeartMate® 
XVE 
Thoratec 
Corporation, 
Pleasanton, Ca, 
USA 
Intracorporeal Pulsatile 
CE mark approval 
2003 
FDA approval for 
BTT 2001 for DT 
2003 
HeartMate 
II® 
Thoratec 
Corporation, 
Pleasanton, Ca, 
USA 
 
Intracorporeal 
Continuous Axial 
flow with blood-
immersed bearings
CE mark approval 
2005 
FDA approval for 
BTT 2008 for DT 
2010  
Jarvik 2000 
Jarvik Heart Inc. 
New York, NY, 
USA 
Intracorporeal 
Continuous Axial 
flow with blood-
immersed bearings
CE  mark approval 
2005 
USA trial BTT in 
progress 
HeartWare® 
HVAD 
HeartWare 
International Inc. 
Framingham, MA, 
USA 
Intracorporeal 
Centrifugal 
Continuous flow 
Hydromagnetic 
rotor suspension 
CE mark approval 
2009 
USA BTT and DT 
trial in progress 
DuraHeart® 
Terumo Heart Inc. 
Ann Arbor, MI, 
USA 
Intracorporeal 
Centrifugal 
Continuous flow 
Magnetically 
levitated impeller 
CE  mark approval 
2007 
USA trial BTT in 
progress 
BTT (Bridge to transplantation); DT (Destination therapy); FDA (Food and Drug Administration); CE 
(European Conformity) 
Table 1. Long term implantable left ventricular assist devices 
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Many VAD centers use a variety of different types of LVADs in their mechanical circulatory 
support programs. Therefore, managing LVAD outpatients with different types of systems 
is not uncommon. Clinicians need to be familiar with the specifics of each device to 
minimize complications. While each device may have its own unique challenges, many of 
the issues are universal to all devices. 
3. Preparing for hospital discharge 
A review of the literature reveals that most mechanical circulatory support programs have 
similar criteria for discharging patients from hospital on LVAD support. See Table 2 for 
general criteria for discharging LVAD patients home.  
 
1. Stable vital signs, LVAD hemodynamics and pump function  
2. Stable hemoglobin and end organ function 
3. Native heart able to support patient in the case of serious VAD malfunction. 
4. Adequate wound healing 
5. Patient is ambulatory-approved for discharge by physiotherapist 
6. Patient able to perform activities of daily living (ADLs) with minimal assistance- 
approved for discharge by occupational therapist 
7. Patient and caregiver complete LVAD training and demonstrate proficiency in  LVAD 
management   
8. Patient and caregiver have completed out of hospital excursions 
9. Notification of emergency medical services, local emergency room staff and electric 
company  
10. List of emergency contacts given to LVAD patient 
11. Outpatient appointment scheduled  
Table 2. Criteria for discharging left ventricular assist device patients home 
The LVAD patient’s medical condition must be determined to be stable before discharge. 
This includes patient’s volume status, LVAD function, medication regime and laboratory 
results. The LVAD patient must be physically capable of managing his or her self care. Self 
care activities include monitoring daily weights, administration of medication, device 
management and exit site care. Completion of a physical and occupational therapy program 
permits LVAD patients to be independent and perform their activities of daily living (ADLs) 
with minimal assistance. Maintaining a stable international normalized ratio (INR) in the 
therapeutic range ensures the risk of bleeding or thromboembolism after discharge is 
minimized.   
Although patient’s medical readiness for discharge is critical, patient and caregiver must be 
knowledgeable on all aspects of the care and operation of the LVAD prior to discharge. 
Patient and caregiver must complete a comprehensive LVAD educational program that 
encompasses routine care to trouble shooting device problems.  Both patient and caregiver 
must be able to respond appropriately to LVAD system alarms and emergency situations. 
Proficiency with changing LVAD batteries and power sources must be demonstrated by 
patient and caregiver. Following extensive training, competency evaluation and skill 
demonstration must be performed by patient and caregiver before discharge. Since 
meticulous care of the LVAD exit site is critical, education emphasizing proper exit site care 
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is essential.  Patient or caregiver must be able to perform independent LVAD exit site 
dressing changes using aseptic technique. Patient and caregiver must be able to monitor the 
device for proper function, identify alarm conditions and know when to contact the VAD 
team for support and assistance. Once the patient and caregiver demonstrate competence 
with their device, it is important for the LVAD patient and caregiver to go on out of hospital 
excursions to foster independence and promote confidence prior to formal discharge. 
4. Community support 
Discharge preparation involves notification of the LVAD patient’s community resources. 
Methods of informing local care providers include providing written material, a training CD 
or LVAD education presentations. VAD coordinators play an important role in coordinating 
the care between local care providers and the VAD team. As LVAD patients may present to 
their local emergency room with urgent LVAD related problems such as arrhythmias, 
device malfunction or stroke, communication between local care providers and the VAD 
team is vital. Instructing local Emergency Medical Services (EMS) personnel and emergency 
room (ER) staff on LVAD emergency measures may be considered. However, ensuring the 
training of all EMS and ER personnel may be difficult. Therefore training the patient and 
their family to direct the actions of EMS and ER personnel in collaboration with the 
personnel at the VAD center may be at better approach (Holman et al., 2001). LVAD patients 
that live a considerable distance from the VAD center may require routine follow up with 
their local cardiologist and primary care physician. Therefore, it is important that local 
physicians are familiar with the device and have access to the VAD team at any time. 
Emergency contact numbers for the patient’s VAD center should be with the LVAD patient 
at all times. Also, community dentists must be informed that VAD patients should receive 
bacterial endocarditis prophylaxis prior to dental procedures. The electric company should 
be notified of the LVAD patient’s dependence on electrical power and need for priority 
status for power restoration should a power failure occur. And lastly, local cardiac 
rehabilitation centers must be given information to safely exercise the VAD patient. Patient 
and community education and support are key elements of a successful outpatient program. 
5. Outpatient follow up  
Follow up in the clinic is an essential component of the care and management of outpatient 
LVADs. See Table 3 for routine outpatient follow up care. The frequency of clinic visits 
 
• Weekly clinic visits that include a physical exam, interrogation of the device, 
laboratory testing, optimization of medical therapy and discussion of patient concerns.  
• All LVAD patients are re-started on heart failure medications. Up titration of ace 
inhibitor and beta blocker is assessed during clinic visits. 
• Routine echocardiograms every month or when clinically indicated to evaluate left 
and right ventricular function, valvular function and estimation of right ventricular 
systolic pressure (RVSP).  Echo based adjustments to VAD speed may be required. 
• Clinic visits are decreased to bi-weekly or monthly when LVAD patients are on 
optimal medical therapy and there are no active issues.  
Table 3. Outpatient LVAD follow up care 
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depends on the patient’s condition, medical issues or concerns with device function. Once 
discharged from hospital, LVAD patients usually return to the outpatient clinic weekly until 
the VAD team determines less frequent visits are warranted. However, an outpatient should 
be assessed whenever there is a significant change in the patient’s medical status, LVAD 
pump readings or any alarm condition occurs. It is critical that the outpatient has access to 
the VAD team at all times for any emergencies or for technical support. Emergency 
procedures should be reviewed in clinic with patient and caregiver on a regular basis.  
6. Discharge rates 
Although LVADs have been in use for nearly two decades, the Food and Drug 
Administration (FDA) only allowed LVAD bridge to transplantation  patients to be 
discharged to their home environment as of 1996 (Park et al., 2005). In 2001, a review of 
outpatient VAD programs revealed that only 40-60% of patients with LVADs awaiting 
cardiac transplantation were discharged (Holman et al., 2001). However as mechanical 
circulatory support programs become more comfortable with discharging patients on LVAD 
support, the number of patients discharged from hospital is increasing. Lietz and colleagues 
reported 71% of destination therapy LVAD patients were discharged home or to a nursing 
facility (Lietz et al., 2007). In a study with bridge to transplantation LVAD patients, 75 % of 
patients with HeartMate II (Thoratec, Pleasanton, CA, USA) continuous flow LVAD were 
discharged from hospital. The median hospital stay after surgery was 25 days. 54% of 
discharged patients required rehospitalization for complications (Miller et al., 2007). Similar 
results were reported by Pagani and associates. In this study with bridge to transplantation 
patients, 78% of patients with HeartMate II LVAD were discharged from hospital with a 
medium hospital stay after surgery of 25 days. 68% of discharged patients required 
rehospitalization (Pagani et al., 2009). In a recent clinical trial of patients who were ineligible 
for cardiac transplantation, 86% of patients with a continuous flow LVAD and 76% of 
patients with a pulsatile LVAD were discharged from hospital. The median length of stay 
after surgery was 27 days with continuous flow device and 28 days with pulsatile device 
(Slaughter et al., 2009).  MacIver and colleagues reported that 71% of LVAD patients were 
discharged home and that complications occurring in the community were low. This study 
found that patients supported for more than 3 months spent 70% of their support time at 
home and this increased to 94 % for patients supported for more than 1 year (MacIver et al., 
2009). As demonstrated in the literature, an increasing number of patients on VAD support 
are discharged from hospitals and outpatient management is crucial to successful LVAD 
outcomes.  
7. Results of long term VAD support 
Management of LVAD patients requires a thorough understanding of the risks and potential 
complications associated with LVAD therapy. Reviewing the literature on mechanical 
circulatory support allows clinicians to identify and manage common LVAD issues and 
adverse events in order to improve patient outcomes and survival. HeartMate VE and XVE 
(Thoratec, Pleasanton, CA, USA) and  Novacor (World Heart, Oakland, CA, USA) have been 
the most widely used and studied long term implantable LVADs. The HeartMate VE LVAD 
was the device used in the REMATCH trial. The 1 and 2 year survival rates of LVAD 
patients in the REMATCH trial was 52% and 23 % respectively.  The most common causes of 
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death in the LVAD group were sepsis (41%), failure of the device (17%) and ischemic stroke 
(10%) (Rose et al., 2001).  Extended follow-up of the REMATCH trial patients confirmed 
survival rates at 1 year and 2 year for patients receiving LVADs was 52% and 29% 
respectively (Park et al., 2005). Outcomes of LVAD destination therapy in the post 
REMATCH era described by Leitz and associates showed relatively no change in the overall 
survival after HeartMate XVE   LVAD implantation. Survival was 56 % and 30.9% at 1 year 
and 2 years respectively. The leading causes of overall mortality included sepsis (29.5%), 
multiorgan failure (12.8%) and right heart failure (8.4%). LVAD failure accounted for 6% of 
deaths (Lietz et al., 2007). However, a more recent study of patients undergoing destination 
therapy with HeartMate XVE demonstrated that long term LVAD destination therapy can 
be improved. Long and his colleagues reported a 2 year survival of 77 % for the LVAD 
destination therapy group as compared with the REMATCH trial rate of 23%. This study 
also had a 38% reduction of adverse events as compared with the REMATCH trial results. 
Causes of death long term were related to LVAD failure (8.7%), infection (8.7%) and 
malignancy (4.3%). Therefore, relative to the REMATCH trial results, the rate of death after 
discharge was decreased by a factor of 2.5 (Long et al., 2008). Although the study was a 
single center experience and not a randomized controlled trial, the results suggest that 
patient selection and advances in LVAD patient management have the potential for 
improving destination therapy outcomes.    
The prospective, non randomized Investigation of Nontransplant-Eligible Patients Who Are 
Inotrope Dependent (INTrEPID) trial compared the outcomes of patients supported on the 
Novacor LVAD with patients treated with optimal medical therapy. The study 
demonstrated that patients with a Novacor LVAD had superior survival rates at 1 year as 
compared to the medical therapy group (27 % vs. 11%). This trial found that stroke (34%) 
and infection (24%) accounted for the majority of deaths in the LVAD group. While 62 % of 
the LVAD patients experienced a stroke or transient ischemic attack during the study, there 
was no mortality attributable to LVAD malfunction (Rogers et al., 2007). Although the 
REMATCH and the INTrEPID trials demonstrated that patients treated with LVAD 
destination therapy had significant improvement in survival compared with optimal 
medical therapy, morbidity due to sepsis, stroke and device failure is common with the first 
generation pulsatile devices.  
Over the past 2 years a rapid growth in the use of continuous flow LVADs and a decline in 
pulsatile LVADs have been observed (Kirklin et al., 2010). In a prospective study, Miller and 
associates reported the survival rate of LVAD patients implanted with HeartMate II LVAD 
as a bridge to cardiac transplantation was 75% at 6 months and 68% at 12 months. The use of 
a continuous flow pump was not without complications. At 6 months, 19% of patients had 
died while on device support, 4 % had medical complications that precluded transplantation 
and 2 % had their devices replaced. Causes of death included sepsis (4%), ischemic stroke 
(4%) multisystem organ failure (3%) hemorrhagic stroke (2%) anoxic brain injury (1.5%), and 
right heart failure (1.5%). This study also reported that percutaneous lead infection occurred 
in 14% of patients but no pump pocket infection was observed (Miller et al., 2007).  
A retrospective European study of LVAD patients who had received a HeartMate II LVAD 
reported a 1 year survival of 69% in the destination therapy group and 63% in the bridge to 
transplant group. Main causes of death were multiple organ failure, in most instances due to 
septic complications, and cerebrovascular accidents (CVA). One third of adverse events 
occurred within the first week post LVAD implant and only one cerebrovascular accident 
occurred after the first 9 days after surgery. There was no mechanical failure of the device. 
Sepsis remained the leading cause of death overall (Strűber et al., 2008).  
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In a recent prospective study by Pagani and associates, the overall survival for patients with 
a HeartMate II LVAD as bridge to transplant was 73% at 1 year and 72% at 18 months. The 
primary causes of death were sepsis (4%), stroke (4% ischemic and 2% hemorrhagic), right 
heart failure (3%) and device related deaths (3%). Only 4.6 % of deaths occurred after 6 
months of device support and included sepsis, LVAD power loss and withdrawal of 
support. Although LVAD replacement occurred in 4% of patients due to device thrombosis 
(1.4%), percutaneous lead wire damage (1.4%) or for device infection ( 0.3%), there were no 
failures of the mechanical pumping mechanism.  Also reported were significant 
improvements in LVAD patients’ functional status, 6-minute walk test and quality of life 
(Pagani et al., 2009). 
Slaughter and colleagues reported their results of a randomized controlled trial comparing 
outcomes in patients with advanced heart failure who were ineligible for transplantation 
and received either a pulsatile flow HeartMate XVE LVAD or a continuous flow HeartMate 
II LVAD. Estimates of the 1 and 2 year survival rates were 68% and 58 % respectively with 
the continuous flow device and 55% and 24 % with the pulsatile device. The leading causes 
of death in patients with continuous flow device were hemorrhagic stroke (9%), right heart 
failure (5%), sepsis (4%) and external power interruption (4%) while the leading cause of 
death in patients with a pulsatile device were hemorrhagic stroke (10%), right heart failure 
(8%), multiorgan failure (7%) and ischemic stroke (5%). Continuous flow LVAD 
significantly improved the probability of survival free from stroke and reoperation for 
device repair or replacement at 2 years (Slaughter et al., 2009). While both devices 
significantly improved patients’ quality of life and functional capacity, the 2 year survival 
rate with the continuous flow device was more than twice the rate with pulsatile device. 
The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 
database first annual report found that cardiovascular causes (including right ventricular 
failure and fatal arrhythmias) and multiorgan failure predominated as early causes of death 
whereas central nervous system events and infection were the most common causes of 
death after the first month of LVAD implantation. Bleeding and infection were the most 
common adverse events both early and later (Kirklin et al., 2008). While pulsatile VADS 
were the only available devices in the first INTERMACS report, the second INTERMACS 
report included data on continuous flow devices. The report demonstrated that continuous 
flow devices have become the preferred choice for bridge to transplantation therapy as 85% 
of LVADs implanted between July 2008 and January 2009 were continuous flow VADS. In 
general, adverse events were reduced in patients with continuous flow devices for device 
malfunction, infection, hepatic dysfunction and neurologic events (Kirklin et al., 2010). A 
review of the studies with HeartMate II LVAD, a second generation device, provides 
evidence of improved outcomes and reduced morbidity with continuous flow pumps as 
compared with pulsatile pumps. Overall there was significant reduction of adverse events 
including percutaneous lead infection and neurological events with the non pulsatile device.  
8. Outpatient LVAD outcomes 
A review of the literature reveals that there is limited research on outpatient outcomes. The 
literature consists mostly of single center reports that are based on small numbers of 
outpatients. Also, the majority of studies describe outpatient outcomes while on pulsatile 
VAD support with very few studies that include non pulsatile VADs. See Table 3 for a 
review of the literature on LVAD outpatient outcomes.  
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Authors  
Study 
period 
Number of 
discharged 
patients 
Device Results 
Myers et al., 
1996 
Unknown 21 HeartMate VE 
15 readmissions to the 
hospital: 9 for medical 
reasons and 6 for device 
related problems.  No deaths 
occurred outside of the 
hospital. Two patients 
returned to full-time 
employment 
Schmid et al., 
1999 
1995-1998 16 
HeartMate VE, 
Novacor 
Reasons for readmission 
included systemic or 
driveline infections, 
suspected or true 
thromboembolic events, 
suspected malfunction of 
LVAD, 1 death due to 
cerebral bleed, 1 death due to 
ventricular fibrillation  
Morales et al., 
2000 
1993-1998 44 HeartMate VE 
None of the outpatients died. 
No strokes occurred. 46% 
minor device malfunctions 
and 6.8 % major device 
malfunctions occurred. 18% 
device related infections  
El-Banayosy et 
al., 2001 
1994-2000 66 
HeartMate VE, 
Novacor 
29 patients were not 
readmitted. Primary reasons 
for readmission were 
neurologic disorders and 
infection complications. 24% 
died on LVAD support (15% 
multiorgan failure and/or 
sepsis, 4.5% cerebral 
infarction, 3% cerebral bleed, 
1.5% brain death) 
Richenbacher & 
Seemuth, 2001 
1999-2001 13 HeartMate VE 
 
1 death due to fungal sepsis 
with embolic event. 62% 
required readmission 
(2 patients with device related 
infections, 2 patients with 
neurologic events, 1 device 
malfunction requiring pump 
replacement, 3 non VAD 
related admissions)  
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Authors  
Study 
period 
Number of 
discharged 
patients 
Device Results 
Holman et al., 
2002 
1997-2001 20 
Thoratec VAD 
( Thoratec 
Corp., 
Pleasanton, 
CA), HeartMate 
VE 
 
5 deaths after hospital 
readmission ( 1 sepsis, 1 
conduit tear, 3 neurologic 
events) 4 device infections, 3 
device malfunctions that 
required pump replacement 
 
 
Drews et al., 
2003 
1996-2001 38 
Novacor,  
Berlin Heart 
( Berlin Heart 
GmbH, 
Germany) 
Total mortality 16%. 2 deaths 
due to cerebral embolism, 1 
death due to cerebral 
hemorrhage, 2 deaths due to 
systemic infection, 1 death 
due to multiorgan failure. 84 
% patients required 
readmission for cerebral 
embolism (9%), bleeding 
(1%), wound infection (24%), 
coagulation disorder (14%), 
non VAD related (46%) 
Frazier et al., 
2007 
2003-2007 35 HeartMate II 
No device malfunctions in 
outpatient setting. 1 device 
removed due to pump pocket 
infection. 1 death due to 
hemorrhagic stroke. 2 
patients had sudden death at 
home. 
Potapov et al., 
2008 
1996-2006 114 
Berlin Heart, 
Novacor, 
MicroMed 
DeBakey 
(MicroMed 
Cardiovascular 
Inc. Houston, 
Tx, USA), 
HeartMate VE, 
DuraHeart, 
Incor ( Berlin 
Heart, 
Germany) 
LionHeart 
(Arrow 
International, 
Inc. Reading, 
PA, USA) 
Outpatients spent 67% time at 
home. 56% readmission 
unrelated to VAD, 20.9% 
wound infection, 10.9% 
coagulation disorders, 7.7% 
cerebral embolism 
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Authors  
Study 
period 
Number of 
discharged 
patients 
Device Results 
 
MacIver et al., 
2009 
2001-2006 17 
HeartMate XVE, 
Novacor,  
HeartMate II 
88% outpatients survived 
until transplant or explant. 1 
death due to cerebral vascular 
accident. 1 subarachnoid 
hemorrhage (patient survived 
to transplant). 29% incidence 
of driveline or pocket 
infection. 29% had device 
malfunction. 1 patient 
remained on support at end 
of study period 
Table 3. Literature on LVAD outpatient outcomes 
Allen and associates published a retrospective review of patients supported more than 1 
year on a Heartmate I or HeartMate II LVAD from 2000 to 2009 which revealed that 
although LVAD support is not without complications, LVAD patients spend the majority of 
time (87%) out of hospital enjoying a good quality of life.  Causes of readmission included 
infection (43.2%), anticoagulation complications (11.5%), gastrointestinal bleeding (8.8%), 
LVAD malfunction (8.1%), neurologic (7.4%). There were 10% of patients that were never 
readmitted while on LVAD support with HeartMate II LVAD. However, 26.7% of patients 
required LVAD exchange for mechanical failure, electrical failure and thrombosis. While 
there was a trend toward higher exchange rates and shorter exchange times with HeartMate 
I, the differences were not statistically significant.  While 77% of LVAD patients required 
additional operations, 57% were related to percutaneous lead or LVAD pocket infections 
(Allen et al., 2010). This study found that device related infections are common no matter 
which generation of device and that they are detrimental to the LVAD patient’s quality of 
life. 
9. Quality of life 
An important aspect to consider for outpatient support is the impact of LVAD therapy on 
quality of life. A majority of patients with advanced heart failure express a strong desire for 
improvements in quality of life and functionality even at the expense of longevity (Rogers et 
al., 2010). The REMATCH trial provided evidence that LVADs improved the quality of life 
for end stage heart failure patients ineligible for transplantation (Rose et al., 2001). A review 
of the literature reveals there is strong evidence that demonstrates the positive effect of long 
term mechanical support on functional capacity.  In a study with patients who received a 
Heartmate VE LVAD, 30% of outpatients were able to return to work or school, 33 % to 
sexual activity and 44% to driving (Morales et al., 2000). Data from advanced heart failure 
patients enrolled in the HeartMate II LVAD trials were analyzed by Rogers and colleagues 
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to assess the impact of continuous flow LVADs on functional capacity and heart failure–
related quality of life. The study found that LVAD patients demonstrated early and 
sustained improvement in functional status and quality of life.  Following implantation with 
HeartMate II LVAD, 82% bridge to transplantation and 80% destination therapy patients at 
6 months and 79 % destination therapy patients at 24 months improved to New York Heart 
Association (NYHA) functional class I or II. Mean 6 minute walk distance in destination 
therapy patients was 204 meters in patients able to ambulate at baseline, which improved to 
350 and 360 meters at 6 and 24 months. There were significant and sustained improvements 
from baseline in both bridge to transplantation and destination therapy patients in median 
Minnesota Living With Heart Failure and Kansas City Cardiomyopathy Questionnaires 
overall summary scores (Rogers et al., 2010). Pagani and his colleagues reported similar 
findings with patients who underwent HeartMate II LVAD implantation as bridge to 
transplantation. At 6 months, there were significant improvements in functional status and 
6-minute walk test (from 0% to 83 % of patients in New York Heart Association functional 
class I or II and from 13% to 89% of patients completing a 6 -minute walk test) and in quality 
of life (mean value improved 41% with Minnesota Living With Heart Failure and 75% with 
Kansas City Cardiomyopathy Questionnaires) (Pagani et al., 2009). While the literature 
shows there is substantial survival benefit and significant improvement in quality of life, 
clinicians must manage and reduce the complications associated with LVAD therapy.   
10. Outpatient medical management 
The literature reveals that device related infection is a major cause of morbidity and 
mortality in LVAD patients. Infection prevention and management is an important aspect of 
LVAD outpatient care. The percutaneous driveline exit site remains the major source of 
device related infections in LVAD patients. It is vital to treat percutaneous driveline 
infections in order to prevent pump pocket infections. The usual organisms cultured are 
Staphylococcus and other biofilm forming organisms such as Pseudomonas, Enterococcus 
and Candida (Holman et al., 2003).  Patients must be taught strict adherence to aseptic 
technique for LVAD exit site care. Another critical component of infection prevention is 
immobilization of the percutaneous driveline to promote tissue ingrowth and reduce 
infection risk. Patients must monitor for signs and symptoms of infections such as fever, 
chills, erythema or tenderness at exit site or along driveline or purulent drainage from exit 
site and notify the VAD team immediately should signs of infection develop. If infection is 
suspected, the clinician should initiate broad spectrum antibiotics once a culture of exit site 
has been obtained.  After the organism is identified the patient should be started on the 
most appropriate antibiotic therapy as per culture and sensitivity results.  Consultation with 
Infectious Diseases Service may be necessary to optimize antibiotic therapy.  
Advanced practice guidelines for HeartMate destination therapy is an excellent resource for 
clinicians and contains care guidelines for infection prevention, management and treatment 
that can be applied to all devices. General recommendations include performing an 
ultrasound or computed tomography (CT) scan to detect presence of fluid accumulation or 
infection (Chinn et al., 2004). If LVAD patient experiences systemic symptoms such as fever, 
chills, leukocytosis, blood cultures should be obtained to exclude bacteremia.  Bacteremia 
must be treated aggressively as it may lead to endocarditis of the pump. If LVAD pocket 
www.intechopen.com
 Ventricular Assist Devices 
 
186 
infection is suspected, incision and drainage may be necessary to obtain cultures.  Increasing 
the LVAD patient’s status on the transplant list may be indicated if patient develops LVAD 
exit site infection. Fungal infections have been associated with vegetative growth on LVADs 
and persistent systemic fungal infection may require LVAD replacement (Thoratec 
Corporation, 2008). While it is possible to treat some patients on an outpatient basis, many 
LVAD patients require rehospitalization for intravenous antibiotic administration for 
driveline exit site infections. MacIver and colleagues reported that 75% of driveline 
infections in outpatient LVADs were managed in the outpatient clinic with a single course 
of oral antibiotics (MacIver et al., 2009).      
Research demonstrates that LVAD patients may experience a neurological event during 
LVAD support. LVAD patients are routinely placed on anticoagulation and antiplatelet 
therapy to decrease the risk of thromboembolic complications during LVAD support. 
Antiplatelet therapy for LVAD patients usually consists of enteric coated aspirin 81 to 325 
mg daily. Some VAD centers add dipyridamole to the antiplatelet regime. For patients 
who have an allergy to aspirin, clopidogrel may be used in its place. 
Thromboelastography can be performed to assess antiplatelet effect. The HeartMate II 
clinical trial found that pump thrombosis was rare with 4% occurring in destination 
therapy patients and 1.4% in bridge to transplantation patients (Slaughter et al., 2010). 
However, as there is a potential for a neurologic event to occur while on LVAD support, it 
is prudent for clinicians to order a computed tomography (CT) scan for any change in the 
mental status of a LVAD patient to assess for subdural hematoma, thromboembolism or 
intracerebral hemorrhage. It is important to maintain adequate pump flows to avoid 
transient ischemic attacks (TIA) or ischemic strokes. Likewise it is critical not to be too 
aggressive with anticoagulation in order to avoid hemorrhagic strokes. A recent study by 
Boyle and associates found that while thrombotic event rates in patients discharged with 
HeartMate II was 3.3%, hemorrhagic event rates were 22%. The gastrointestinal system 
was identified as the most frequent site of bleeding in outpatients. In Boyle’s analysis of 
outpatient anticoagulation, 9.4% of patients discharged from hospital on HeartMate II 
support required blood transfusions due to gastrointestinal bleeding (Boyle et al., 2009). 
Outpatient LVAD management must include regular testing of anticoagulation and 
complete blood counts. Anticoagulation and antiplatelet therapy must be carefully 
monitored to avoid adverse events and may need to be adjusted to minimize risks of 
thromboembolism or hemorrhage. 
Device malfunction is a potential complication that can occur in the outpatient setting. 
Diagnosing device malfunctions can be accomplished by interrogating the device on a 
routine basis. LVAD malfunctions can include controller failure, LVAD motor issues or 
percutaneous lead problems. LVAD patients must notify the VAD team whenever an alarm 
condition occurs. Teaching the LVAD patient to monitor for changes in pump readings 
enables patients to notify the VAD team whenever there are significant changes. Technical 
support from VAD manufacturers is available to assist clinicians and waveforms can be 
down loaded and sent for analysis. It is important for clinicians to accurately diagnose and 
manage LVAD malfunctions to prevent serious adverse events. Patients must be trained to 
recognize and respond to device problems.    
Arrhythmias may occur in patients on LVAD support. Ambardeker and associates reported 
that 24% of LVAD patients in their study received an appropriate implantable cardioverter-
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defibrillator (ICD) shock for a ventricular arrhythmia (Ambardeker et al., 2010). In order to 
avoid potential arrhythmias, it is important for clinicians to closely monitor and correct 
electrolyte imbalances. LVAD patients should be considered for placement of an ICD as 
prophylactic treatment for ventricular arrhythmias. Anti-arrhythmics or beta blockers may 
also be used to suppress ventricular arrhythmias. For patients supported on a continuous 
flow device, it is important to avoid setting the pump speed too high as this may result in a 
suction induced arrhythmia.  
11. Conclusion 
LVAD support has become an accepted standard of care for patients with advanced heart 
failure. The literature demonstrates that LVAD patients can be safely and effectively 
managed as outpatients in the community. Minor LVAD complications can be managed in 
an outpatient LVAD clinic and most LVAD outpatients spend the majority of their time out 
of hospital. However, serious adverse events may require LVAD outpatients to be 
readmitted to hospital for care. In general, driveline infection is the most common 
complication reported in the outpatient setting with both pulsatile and continuous flow 
devices. The literature reveals that due to the limited durability of pulsatile VADs, there has 
been an increase in the number of patients implanted with continuous flow LVADs. A 
review of recent clinical studies demonstrates that there are fewer device related 
complications with continuous flow LVADs. However, the development of continuous flow 
LVADs has resulted in the creation of new clinical problems. Frazier and colleagues found 
that continuous flow introduces physiologic phenomena such as arteriovenous 
malformation leading to gastrointestinal bleeding, septal shift with resultant right heart 
failure, thrombosis of the aortic valve non coronary sinus, aortic valve fusion and aortic 
valve insufficiency (Frazier et al., 2007). Further research is required to determine the 
durability and potential long term problems that may arise with long term use of 
continuous flow LVADs. Longer duration follow up of destination therapy patients on 
continuous flow LVAD support may reveal new issues with non pulsatile devices.  
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